Core Points - The company held its fourth temporary board meeting of the ninth session on August 25, 2025, with all nine directors present, meeting the legal quorum requirements [1] - The board approved the 2025 semi-annual report and its summary, with a unanimous vote of 9 in favor [2] - The board also approved a special report on the use of raised funds for the first half of 2025, again with a unanimous vote [2] - A resolution was passed for the company's subsidiaries to apply for a total credit limit of up to 1.623 billion yuan from banks, with a maximum term of 5 years [2][3] - The board authorized the management team to handle all credit-related procedures within the approved limit without needing further board approval [3] - The board approved a guarantee for a subsidiary, Zhejiang Huahai Jiancheng Pharmaceutical Co., Ltd., for a bank credit limit of up to 205 million yuan [3][5] - The authorization for the guarantee is valid for one year from the date of board approval [3][5]
华海药业: 浙江华海药业股份有限公司第九届董事会第四次临时会议决议公告